Botanix Pharmaceuticals Limited

ASX (AUD): Botanix Pharmaceuticals Limited (BOT)

Last Price

0.32

Today's Change

+0.005 (1.58%)

Day's Change

0.31 - 0.325

Trading Volume

3,655,070

Profile
BOT

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Howie McKibbon Dr. Howie McKibbon

Full Time Employees:  11 11

IPO Date:  1988-01-31 1988-01-31

CIK: 

ISIN:  AU000000BOT2 AU000000BOT2

CUSIP:  Q1698B128 Q1698B128

Beta:  1.87 1.87

Last Dividend:  0.00 0.00

Dcf Diff:  0.27 0.27

Dcf:  0.05 0.05

Description

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

Address

D2, 661 Newcastle Street,
Leederville, WA 6007, AU

61 8 6555 2945

http://www.botanixpharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment